Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases [6] - The company has entered into an exclusive distribution agreement for ProIBS® in Australia and New Zealand, expanding its product portfolio [1][4] Product Information - ProIBS® is a certified medical device designed to treat symptoms of irritable bowel syndrome (IBS), including abdominal pain, bloating, and bowel movement issues [3] - The product contains AVH200®, derived from Aloe barbadensis Miller, which supports the intestinal mucosal barrier and is suitable for long-term use [3] - A usability study indicated that 94% of users found ProIBS® helpful, with 91% reporting an improvement in daily life and 98% willing to recommend it [3] Market Context - IBS affects approximately 30% of the population, with females being more likely to be affected [2] - The IBS treatment market in Australia is part of the broader "Digestives & Intestinal Remedies" market, projected to generate around AU$221.14 million in 2025, with an annual growth rate of 3.28% [2] Strategic Insights - The Chief Commercial Officer of Immuron highlighted the opportunity to expand the digestive health portfolio with ProIBS®, leveraging the success of the Travelan® brand [4] - The CEO of Calmino group AB expressed confidence in the collaboration with Immuron, recognizing Australia and New Zealand as significant markets with growth potential [5]
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)